Skip to Content

Piqray (alpelisib) Disease Interactions

There are 6 disease interactions with Piqray (alpelisib):

Moderate

Alpelisib (applies to Piqray) cutaneous manifestations

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Dermatitis - Drug-Induced

Severe cutaneous reactions, including Stevens-Johnson Syndrome (SJS) and Erythema Multiforme (EM) were reported in patients treated with alpelisib. Do not initiate alpelisib treatment in patients with a history of SJS, EM, or Toxic Epidermal Necrolysis (TEN). If signs or symptoms of severe cutaneous reactions occur, interrupt treatment until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended. If SJS, TEN, or EM is confirmed, permanently discontinue alpelisib. Do not reintroduce alpelisib in patients who have experienced previous severe cutaneous reactions during treatment.

Moderate

Alpelisib (applies to Piqray) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Severe hyperglycemia, including ketoacidosis, has been reported in patients treated with alpelisib. Before initiating treatment with alpelisib it is recommend to test, optimize and monitor blood glucose as clinically indicated. Care should be exercised when using this agent in diabetic patients. Patients with a history of diabetes mellitus may require intensified diabetic treatment. Based on the severity of the hyperglycemia, alpelisib may require dose interruption, reduction, or discontinuation. Advise patients of the signs and symptoms of hyperglycemia. Closely monitor patients with diabetes.

Moderate

Alpelisib (applies to Piqray) diarrhea

Moderate Potential Hazard, Moderate plausibility.

Severe diarrhea, including dehydration and acute kidney injury, occurred in patients treated with alpelisib. Based on the severity of the diarrhea, alpelisib may require dose interruption, reduction, or discontinuation. Care should be exercised when using this agent in patients with diarrhea. Advise patients to start antidiarrheal treatment, increase oral fluids, and notify their healthcare provider if diarrhea occurs while taking alpelisib.

Moderate

Alpelisib (applies to Piqray) osteonecrosis of the jaw

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Osteonecrosis of Jaw

Osteonecrosis of the jaw (ONJ) has been reported in patients using alpelisib. Caution is advised when this drug and bisphosphonates or denosumab are used either simultaneously or sequentially. Do not initiate treatment with alpelisib in patients with ongoing osteonecrosis of the jaw from previous or concurrent treatment with bisphosphonates or denosumab. Patients experiencing ONJ should be managed according to clinical practice.

Moderate

Alpelisib (applies to Piqray) pneumonitis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Interstitial Pneumonitis, Pleuropulmonary Infection

Severe pneumonitis, including acute interstitial pneumonitis and interstitial lung disease, has been reported in patients treated with alpelisib. It is recommended to interrupt alpelisib immediately and evaluate the patient for pneumonitis in patients who have new or worsening respiratory symptoms or are suspected to have developed pneumonitis. Advise patients to immediately report new or worsening respiratory symptoms. Permanently discontinue alpelisib in all patients with confirmed pneumonitis.

Moderate

Alpelisib (applies to Piqray) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

No dose adjustment is recommended for patients with mild to moderate renal impairment (CrCl 30 to < 90 mL/min). Close monitoring is recommended when using alpelisib in patients with severe renal impairment (CrCl < 30 mL/min) as its effect on the pharmacokinetics is unknown.

Piqray (alpelisib) drug interactions

There are 283 drug interactions with Piqray (alpelisib)

Piqray (alpelisib) alcohol/food interactions

There are 2 alcohol/food interactions with Piqray (alpelisib)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.